In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
|Articles|August 6, 2008
APPI Joins Initiative to Transform Clinical Trials
The Academy of Pharmaceutical Physicians and Investigators (APPI), a nonprofit group of nearly 1,200 physician members involved in the clinical research enterprise, has joined the Clinical Trials Transformation Initiative (CTTI).
Advertisement
APPI Joins Initiative to Transform Clinical Trials
Alexandria, Va.-The Academy of Pharmaceutical Physicians and Investigators (APPI), a nonprofit group of nearly 1,200 physician members involved in the clinical research enterprise, has joined the Clinical Trials Transformation Initiative (CTTI).
The CTTI was founded recently by the U.S. Food and Drug Administration (FDA) and Duke University as a public-private partnership of organizations that seeks to improve the quality and efficiency of clinical trials in the United States. As described at https://www.trialstransformation.org, CTTI was formed in the wake of growing frustration among patients, consumers, the academic community, and industry over the difficulty of conducting high-quality clinical trials in a timely manner that could produce information physicians need to define optimal treatments for their patients.
“As the leaders of the clinical research teams that test the safety and efficacy of potential new drugs and devices, physician investigators are in the prime position to spearhead efforts to make the trials process work better,” says Charles M. Alexander, MD, FACP, FACE, president-elect of APPI. “Our goal in joining CTTI is to support its collaborative efforts on behalf of everyone from the human subject volunteers in clinical trials to the researchers to the patients who will benefit in the future from FDA-approved products.”
As a contributing member of CTTI, APPI will choose one representative from among its membership to serve on CTTI’s Steering Committee. The Steering Committee representative from APPI may nominate other individuals from within APPI to work on project teams or special interest groups, should they be formed.
APPI is an affiliate of the Association of Clinical Research Professionals (ACRP), an Alexandria, Va.-based nonprofit group with nearly 20,000 members worldwide from the clinical research team. Prior to its affiliation with ACRP in 2005, APPI had been known as the American Academy of Pharmaceutical Physicians. APPI has chapters in California, District of Columbia, Illinois, Kansas, Massachusetts, New Jersey, North Carolina, and Pennsylvania, and is the certification body offering the Certified Physician Investigator (CPI™) examination.
For more information about APPI, please visit http://www.appinet.org.
Advertisement
Related to this article
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
What "Patient Voice" Actually Requires: Beyond the Buzzword
5